S&P Global upgrades Biocon Biologics credit rating To 'BB+'

Biocon Biologics has received a credit rating upgrade from S&P Global Ratings. The company's long-term issuer credit rating is now 'BB+' with a stable outlook. This upgrade follows Biocon's simplification of its capital structure and reduction of debt. New product launches and industry trends are expected to support Biocon's earnings growth in the coming years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EBvlO6z
via IFTTT